EUVIMEDEUVIMED entdecken
Crossref

Exploring the Topoisomerase II Inhibitory Potential of Steroidal Drugs as a Recommended Mechanism of Action for Their Anticancer Activity: In Silico and In Vitro Assessments

Ahmed A Al-Karmalawy iD, Mohamed E Eissa, Ayman Abo Elmaaty iD, Tarek A Yousef iD, Arwa Omar Al Khatib iD, Radwan Alnajjar iD, Faten Farouk iD, Amany Belal, Abdullah Yahya Abdullah Alzahrani, Marwa Sharaky iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Ahmed A Al-Karmalawy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad, Iraq. Hauptthemen laut MEDLINE: Antineoplastic Agents, Topoisomerase II Inhibitors, Steroids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) (grant number IMSIU-DDRSP2501)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein, and based on the pharmacophoric features of doxorubicin (Dox); 133 steroids were screened to assess their ability to act as TOP II inhibitors for the discovery of those with promising anticancer activity. The cytotoxic inhibitory concentration 50 (IC 50 ) of the investigated steroids was determined against H1299, CaCo2, MDA‐MB‐468, and FaDu cancer cell lines and compared to Dox. Fluticasone propionate and fusidic acid exhibited the most potent antiproliferative effect against the MDA‐MB‐468 with IC 50 values of 10.4 ± 0.7 and 10.6 ± 1.7 μM, respectively. On the other hand, the outstanding antitumor members (beclomethasone dipropionate, fluticasone propionate, prednisolone, dexamethasone, and fusidic acid) were further investigated for their TOP II inhibitory potentials. Where the protein expression of TOP II was downregulated by 0.79, 0.76, and 0.67‐fold change for fusidic acid, fluticasone propionate, and dexamethasone, respectively, compared to the control. Besides, the examined steroidal candidates were subjected to a molecular docking study towards the TOP II receptor in comparison to Dox and the co‐crystallized ligand (EVP) as references. Moreover, molecular dynamics (MD) simulations were conducted on the aforementioned steroids along with Dox and EVP for 200 ns to validate the docking results. Consequently, steroids, in particular fusidic acid, fluticasone propionate, and dexamethasone, can be regarded as promising lead compounds targeting TOP II for cancer treatment along with their typical anti‐inflammatory effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsTopoisomerase II InhibitorsSteroidsHumansMolecular Docking SimulationCell Line, TumorDNA Topoisomerases, Type IICell ProliferationDoxorubicinInhibitory Concentration 50

Stichwörter der Autor:innen

ELISAcancermolecular dynamicssteroidstopoisomerase II

Substanzen

Antineoplastic AgentsTopoisomerase II InhibitorsDNA Topoisomerases, Type IISteroidsDoxorubicin

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad, Iraq.
  • College of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
  • Faculty of Pharmacy, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.

ORCID-Profile: Ahmed A Al-Karmalawy, Ayman Abo Elmaaty, Tarek A Yousef, Arwa Omar Al Khatib, Radwan Alnajjar, Faten Farouk, Marwa Sharaky

Förderung

  • This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) (grant number IMSIU-DDRSP2501).

Zitieren

APA

Al-Karmalawy, A. A., Eissa, M. E., Elmaaty, A. A., Yousef, T. A., Khatib, A. O. A., Alnajjar, R., Farouk, F., Belal, A., Alzahrani, A. Y. A., & Sharaky, M. (2025). Exploring the Topoisomerase II Inhibitory Potential of Steroidal Drugs as a Recommended Mechanism of Action for Their Anticancer Activity: In Silico and In Vitro Assessments. Drug Development Research. https://doi.org/10.1002/ddr.70152

Vancouver

Al-Karmalawy AA, Eissa ME, Elmaaty AA, Yousef TA, Khatib AOA, Alnajjar R, et al. Exploring the Topoisomerase II Inhibitory Potential of Steroidal Drugs as a Recommended Mechanism of Action for Their Anticancer Activity: In Silico and In Vitro Assessments. Drug Development Research. 2025. doi:10.1002/ddr.70152

BibTeX
@article{AlKarmalawy2025,
  author = {Al-Karmalawy, Ahmed A and Eissa, Mohamed E and Elmaaty, Ayman Abo and Yousef, Tarek A and Khatib, Arwa Omar Al and Alnajjar, Radwan and Farouk, Faten and Belal, Amany and Alzahrani, Abdullah Yahya Abdullah and Sharaky, Marwa},
  title = {Exploring the Topoisomerase II Inhibitory Potential of Steroidal Drugs as a Recommended Mechanism of Action for Their Anticancer Activity: In Silico and In Vitro Assessments},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70152}
}
Kostenlos starten →